Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical Ruxolitinib for Cutaneous cGVHD
NCT03395340Phase 2Terminated
- Sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases
- Start
- Nov 2018
- Primary completion
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ruxolitinib cream in chronic graft-versus-host disease (cGVHD), sponsored by National Institute of Arthritis and Musculoskeletal and Skin Diseases. Started Nov 2018; status: terminated.
02
Drugs
ruxolitinib cream
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on NCT03395340.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03395340.